

Resource Summary Report

Generated by RRID on Aug 9, 2026

CD133/2 (AC141)-PE, human

RRID:AB_244348

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-080-901, RRID:AB_244348

Antibody Information

URL: http://antibodyregistry.org/AB_244348

Proper Citation: Miltenyi Biotec Cat# 130-080-901, RRID:AB_244348

Target Antigen: CD133/2 (AC141)

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 2021; Target Distribution brain, endothelial cells, epithelial cells, heart, hematopoietic stem cells, kidney, liver, lung, pancreas, placenta, ES and iPS cells, red blood cells; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-120-059. (RRID:AB_2783940).

Antibody Name: CD133/2 (AC141)-PE, human

Description: This monoclonal targets CD133/2 (AC141)

Target Organism: human

Clone ID: AC141

Antibody ID: AB_244348

Vendor: Miltenyi Biotec

Catalog Number: 130-080-901

Record Creation Time: 20250820T061250+0000

Record Last Update: 20250820T233239+0000

Ratings and Alerts

No rating or validation information has been found for CD133/2 (AC141)-PE, human.

Warning: Discontinued: 2021

Discontinued: 2021; Target Distribution brain, endothelial cells, epithelial cells, heart, hematopoietic stem cells, kidney, liver, lung, pancreas, placenta, ES and iPS cells, red blood cells; target type CD markers; tested applications MACS Flow Cytometry; quantity: Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-120-059. (RRID:AB_2783940).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chan LH, et al. (2018) PRMT6 Regulates RAS/RAF Binding and MEK/ERK-Mediated Cancer Stemness Activities in Hepatocellular Carcinoma through CRAF Methylation. Cell reports, 25(3), 690.